Dura trying to extend its model

Dura Pharmaceuticals Inc. was one of the darlings of Wall Street in 1997, with its strategy of in-licensing and acquisition to build complementary respiratory product lines.

But the company experienced how quickly that can change in early 1998, when it failed to make an expected acquisition and weak sales led the company to announce it would have to expand its sales force to halt softening sales and prepare for launch of its Spiros Albuterol asthma product. A delay in approval of Spiros late last year was the icing on a bad year.